Palbociclib
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | <StructureSection load='' size='340' side='right' caption=' | + | <StructureSection load='' size='340' side='right' caption='Palbociclib' scene='10/1001138/Cv/1'> |
Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. See also [https://en.wikipedia.org/wiki/Palbociclib Palbociclib]. It is a selective inhibitor of the [[cyclin-dependent kinases]] CDK4 and CDK6 (see also [[CDK4]]).<ref name="a2">PMID:19874578</ref><ref name="a3">PMID:24369047</ref> | Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. See also [https://en.wikipedia.org/wiki/Palbociclib Palbociclib]. It is a selective inhibitor of the [[cyclin-dependent kinases]] CDK4 and CDK6 (see also [[CDK4]]).<ref name="a2">PMID:19874578</ref><ref name="a3">PMID:24369047</ref> | ||
Current revision
| |||||||||||
References
- ↑ Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, Ginther C, Atefi M, Chen I, Fowst C, Los G, Slamon DJ. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11(5):R77. PMID:19874578 doi:10.1186/bcr2419
- ↑ Rocca A, Farolfi A, Bravaccini S, Schirone A, Amadori D. Palbociclib (PD 0332991) : targeting the cell cycle machinery in breast cancer. Expert Opin Pharmacother. 2014 Feb;15(3):407-20. PMID:24369047 doi:10.1517/14656566.2014.870555
- ↑ Xu H, Yu S, Liu Q, Yuan X, Mani S, Pestell RG, Wu K. Recent advances of highly selective CDK4/6 inhibitors in breast cancer. J Hematol Oncol. 2017 Apr 24;10(1):97. PMID:28438180 doi:10.1186/s13045-017-0467-2
